Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin ...

On Friday, Novo Nordisk A/S NVO released topline results ... Also Read: Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations The primary endpoint was the treatment ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...